Development of anti-HCV therapy the regulation of NS5A function
Development of anti-HCV therapy the regulation of NS5A function
批准号:
12557053
负责人:
ENOMOTO Nobuyuki
金额:
$7.49万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2002
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Hepatitis C virus (HCV) subgenomic replicon has been reported to replicate efficiently and continuously in human hepatoma Huh-7 cells. To extend the previous results to other isolated HCV clones, we have constructed another HCV replicon from HC-J4, one of the chimpanzee-infectious clones. An HCV-replicon derived from HC-J4 (RpJ4) consists of HCV-5'-UTR, neomycin phosphotransferase gene, the encephalomyocarditis virus IRES, HCV-nonstructural region, NS3 to NS5B, and HCV-3'-UTR. The adaptive mutations known to be required for HCV-Conl replicon were introduced in RpJ4 replicon, aa.(amino acids number according to HC-J4) 2197 serine to proline, deletion of serine at aa.2201, and aa.2204 serine to isoleucine (RpJ4-S2I97P, RpJ4-S22001del, and RpJ4-S2204I). RpJ4/ISDRmutant and RpJ4-S2201del/ISDRmutant were also constructed by introducing six amino acid mutations into the interferon sensitivity determining region (ISDR). Replicon RNA was transfected into Huh-7 cells, and stable replicon-expressing cell lines were established by G418 selection. After transfection to naive Huh-7 cells, RpJ4 and RpJ4/ISDRmutants did not produce any G418-resistant colonies. In contrast, G418-resistant cells were transduced efficiently by RpJ4-S2197P, RpJ4-S2204I, RpJ4-S2201del and RpJ4-S2201del/ISDRmutants, with the RpJ4-S2201del/ISDRmutant being most efficient. In conclusion, The HCV replicon derived from HC-J4 can replicate efficiently following the introduction of adaptive mutations into the upstream region of ISDR. Moreover, additional introduction of mutations into ISDR further enhances its replication. These findings demonstrate that the genetic structure of the NS5A domain is critical in HCV-1b replications.
期刊论文(24)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Nagayama K, Enomoto N, Izumi N, Kurosaki M, Miyasaka Y, Watanabe H, Itakura J, Chen C-H, Tazawa J, Ikeda T, Marumo F, Sato C.: "Sequences in the NS5A Protein of Genotype 1b Hepatitis C Virus and the Serum ALT Response to Interferon Therapy in Japanese Pat
Nagayama K、Enomoto N、Izumi N、Kurosaki M、Miyasaka Y、Watanabe H、Itakura J、Chen C-H、Tazawa J、Ikeda T、Marumo F、Sato C.:“基因型 1b 丙型肝炎病毒的 NS5A 蛋白序列和
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Watanabe, H, Enomoto, N, et al.: "Number and Position of Mutations in the Interferon Sensitivity-Determining Region of the Gene for Nonstructural Protein 5A Correlates with Interferon Efficacy in Hepatitis C Virus Genotype 1b Infection"J Infect Dis. 183.
Watanabe, H, Enomoto, N 等人:“非结构蛋白 5A 基因干扰素敏感性决定区域中突变的数量和位置与丙型肝炎病毒基因型 1b 感染中的干扰素功效相关”J Infect Dis。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Nagayama, K, Enomoto, N, et al.: "Overexpression of interferon gamma-inducible protein 10 in the liver of patients with type I autoimmune hepatitis identified by suppression subtractive hybridization"Am J Gastroenterol. 96. 2211-2217 (2001)
Nagayama, K, Enomoto, N 等人:“通过抑制消减杂交鉴定出 I 型自身免疫性肝炎患者肝脏中干扰素 γ 诱导蛋白 10 的过度表达”Am J Gastroenterol。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Itakura, J, Enomoto, N, et al.: "CD81 Nucleotide Mutation in Hepatocellular Carcinoma and No CD81 Polymorphism in Patients with Various Stages of Hepatitis C Virus Infection"J Med Virol. 63. 22-28 (2001)
Itakura, J, Enomoto, N 等人:“肝细胞癌中的 CD81 核苷酸突变和丙型肝炎病毒感染各个阶段的患者中无 CD81 多态性”J Med Virol。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Yu S-H, Nagayama K, Enomoto N, Izumi N, Marumo F, Sato C.: "Intrahepatic mRNA expression of interferon-gamma inducible antiviral genes in liver diseases : PKR overexpression and RNase L inhibitor suppression in chronic hepatitis C"Hepatology. 32. 1089-109
Yu S-H、Nagayama K、Enomoto N、Izumi N、Marumo F、Sato C.:“肝病中干扰素-γ诱导型抗病毒基因的肝内 mRNA 表达:慢性丙型肝炎中 PKR 过度表达和 RNase L 抑制剂抑制”肝病学。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 12 条
Next-generation sequence of cancer-related genes in digestive organ cancers using clinical samples
-
批准号:26670380
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.33万
-
财政年份:2014
-
负责人:ENOMOTO Nobuyuki
-
依托单位:
Clarifying the pathogenesis of chronic hepatitis C through comprehensive genetic analyses of the virus and host using next-generation sequencer
-
批准号:23390195
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$12.4万
-
财政年份:2011
-
负责人:ENOMOTO Nobuyuki
-
依托单位:
Analysis ofchronic viral hepaptis by the large-scale next generation sequeincing
-
批准号:21659186
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.11万
-
财政年份:2009
-
负责人:ENOMOTO Nobuyuki
-
依托单位:
Comprehensive analysis of chronic hepatitis C by large-scale viral genome wide analysis
-
批准号:20390206
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.98万
-
财政年份:2008
-
负责人:ENOMOTO Nobuyuki
-
依托单位:
Analysis of anti-interferon mechanism by HCV NS5A protein using HCV replicon system
-
批准号:14370175
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$8.83万
-
财政年份:2002
-
负责人:ENOMOTO Nobuyuki
-
依托单位:
Analysis of liver diesease related gene expression using subtraction cloning
-
批准号:12670467
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.5万
-
财政年份:2000
-
负责人:ENOMOTO Nobuyuki
-
依托单位:
Function of HCV NS5A protein and the mechanism of interferon resistance
-
批准号:10670456
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.43万
-
财政年份:1998
-
负责人:ENOMOTO Nobuyuki
-
依托单位:
Elucidation of Interferon Sensitivity Determining Region in Hepatitis C Virus Genome
-
批准号:06670525
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.47万
-
财政年份:1994
-
负责人:ENOMOTO Nobuyuki
-
依托单位:
国内基金
海外基金
登录
查看更多内容
三种凤尾蕨属植物中吡咯生物碱及其抗菌和抗HCV病毒功能研究
-
批准号:82360689
-
项目类别:地区科学基金项目
-
资助金额:32.00万元
-
批准年份:2023
-
负责人:邹娟
-
依托单位:
KIR/HLAI基因遗传变异及HCV逃逸突变与感染免疫应答相关性的分子流行病学及机制研究
-
批准号:82273691
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:岳明
-
依托单位:
基于“逆向免疫学”理论筛选具有交叉保护作用的抗HCV抗原表位的研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:边中启
-
依托单位:
云南省HCV感染人群C19orf66基因遗传易感性分析及其机制研究
-
批准号:32160148
-
项目类别:地区科学基金项目
-
资助金额:34万元
-
批准年份:2021
-
负责人:张阿梅
-
依托单位:
抗HCV病毒解旋酶的研究及其小分子抑制剂发现
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2021
-
负责人:邢曦雯
-
依托单位:
HCV NS3蛋白调控circ_0001175/miR-130a/MDM4/P53通路参与肝癌发生发展的作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:
-
依托单位:
P38 MAPK信号通路介导BmKDfsin3/4动物毒液多肽家族抗HBV/HCV及相关肝细胞癌的作用与机制
-
批准号:--
-
项目类别:--
-
资助金额:150万元
-
批准年份:2021
-
负责人:曹志贱
-
依托单位:
P38MAPK信号通路介导BmKDfsin3/4动物毒液多肽家族抗HBV/HCV及相关肝细胞癌的作用与机制
-
批准号:3211101002
-
项目类别:国际(地区)合作与交流项目
-
资助金额:0.00万元
-
批准年份:2021
-
负责人:曹志贱
-
依托单位:
HBV/HCV重叠感染下DAA抗HCV治疗通过影响IFIT1和miR-122表达参与调控HBV再激活的机制研究
-
批准号:LQ21H190003
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:刘范伟
-
依托单位:
具有抗HCV活性倍半萜低聚物的发现及其作用机制研究
-
批准号:32000280
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:严欢
-
依托单位: